Pipeline Previews

Individual clinicians, clinical organizations, educators, safety advocates, standard setting bodies, and other surgical team members are encouraged to join in this effort to rid surgical environments of the hazards associated with plume inhalation.

Buffalo Filter is pleased to announce LaparoVue^™ Visibility System our newest entry into the laparoscopic market. Understanding a surgeon’s need to see clearly during laparoscopic surgery, LaparoVue is an all-in-one solution designed to take the complexity out of achieving optimal visualization. An easy to use, disposable multipurpose device that warms, white balances, cleans and defogs, LaparoVue eliminates the necessity for multiple product purchases.

Promius Pharma, LLC, has acquired the rights to market and distribute Trianex^® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of a cream.

Trianex Ointment will be available in a 430 gram jar and features a proprietary cream-like formulation. It will be the only ointment to offer this combination, making it an appealing option for those patients with inflammatory skin conditions that cover large areas and who don’t like the typical greasy feel of ointments.

Provectus Biopharmaceuticals, Inc. announced that it has received U.S. Patent No. 8,974,363 from the United States Patent and Trademark Office (USPTO). The new patent, entitled "Topical medicaments and methods for photodynamic treatment of disease," provides detailed protection of the Company's investigational dermatological drug PH-10.

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis.